Aromatase Gene Polymorphism Does Not Influence Clinical Phenotype and Response to Oral Contraceptive Pills in Polycystic Ovary Syndrome Women

2012 ◽  
Vol 74 (2) ◽  
pp. 136-142 ◽  
Author(s):  
Polyana S. Maier ◽  
Poli Mara Spritzer
Keyword(s):  
Oral Contraceptive ◽  
Polycystic Ovary Syndrome ◽  
Gene Polymorphism ◽  
Clinical Phenotype ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
Oral Contraceptive Pills ◽  
Aromatase Gene ◽  
Contraceptive Pills

Persistence with Oral Contraceptive Pills Versus Metformin in Women with Polycystic Ovary Syndrome

2012 ◽  
Vol 21 (6) ◽  
pp. 690-694 ◽  
Author(s):  
Nicole W. Karjane ◽  
Kai I. Cheang ◽  
Gabriela A. Mandolesi ◽  
Dale W. Stovall
Keyword(s):  
Oral Contraceptive ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
Oral Contraceptive Pills ◽  
Contraceptive Pills

scholarly journals Influence of oral contraceptive pills on phenotype expression in women with polycystic ovary syndrome

2005 ◽  
Vol 11 (6) ◽  
pp. 690-696 ◽  
Author(s):  
Annemarie GM Mulders ◽  
Marianne ten Kate—Booij ◽  
Richard Pal ◽  
Marjolijn De Kruif ◽  
Lizka Nekrui ◽  
...  
Keyword(s):  
Oral Contraceptive ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
Oral Contraceptive Pills ◽  
Contraceptive Pills ◽  
Phenotype Expression

A Modern Medical Quandary: Polycystic Ovary Syndrome, Insulin Resistance, and Oral Contraceptive Pills

2003 ◽  
Vol 88 (5) ◽  
pp. 1927-1932 ◽  
Author(s):  
Evanthia Diamanti-Kandarakis ◽  
Jean-Patrice Baillargeon ◽  
Maria J. Iuorno ◽  
Daniela J. Jakubowicz ◽  
John E. Nestler
Keyword(s):  
Insulin Resistance ◽  
Oral Contraceptive ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
Oral Contraceptive Pills ◽  
Contraceptive Pills

scholarly journals Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome

2018 ◽  
Vol 10 ◽  
pp. 204201881880567
Author(s):  
Huda Alalami ◽  
Thozhukat Sathyapalan ◽  
Stephen L. Atkin
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
Pharmacological Agents ◽  
Oral Contraceptive Pills ◽  
Contraceptive Pills ◽  
Increased Risk ◽  
Dipeptidyl Peptidase Iv Inhibitors ◽  
Onset Of Diabetes ◽  
Glucagon Like Peptide 1

Women with polycystic ovary syndrome (PCOS) have an adverse metabolic profile with an increased risk of prediabetes and type 2 diabetes (T2DM); however, it is unclear if PCOS is associated with increased cardiovascular events in later years independent of the presence of T2DM. Many therapies have been used to treat the differing facets of PCOS, including those for menstrual irregularity, hirsutism, acne and anovulatory infertility. The aim of this review was to evaluate the cardiovascular profiles associated with the medications used in the management of PCOS and evaluate whether they have cardiovascular benefit, detriment or are neutral. The medications reviewed include oral contraceptive pills, antiandrogens, clomiphene and drugs specifically used in diabetes therapy; metformin, glitazones, dipeptidyl peptidase IV inhibitors and glucagon-like peptide-1 receptor agonists. This review concludes that therapies that are used to treat these patients appear not to add to the cardiovascular risk and that there is no evidence that any interventional medical therapy may prevent the onset of diabetes in patients with PCOS, though in the case of metformin, this agent may be beneficial in preventing development of gestational diabetes.

Sign in / Sign up

Export Citation Format

Share Document